SpectraCure's patent application for a new technology, to improve the company's IDOSE® technology, has been approved by the European Patent Office, EPO. The IDOSE® technology is central to SpectraCure's method of treating prostate cancer with photodynamic tumor therapy (PDT). In short, IDOSE® technology means that the prostate tissue is monitored during treatment with a series of different measurements to ensure that the correct dose is given, so that the tumour is eliminated, without damaging healthy surrounding tissue.
The new patent protects a method for detecting and compensating for bleeding in the tissue that can otherwise affect how the laser light is delivered into the prostate tissue. This method ensures, in a better way than with previous methods, that the correct laser light dose is delivered to the tissue, which in the long run has the potential to lead to an improved treatment effect.
As previously announced, the patent has been approved in the USA and is also under review in several other countries that represent SpectraCure's largest and most important future markets.
SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.
The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, email@example.com, tel +468-503 00 050, and trades under the short name SPEC.